LianBio Competitors

Delisted . USA . 
Stock . LianBio ADR
LIANDelisted Stock  USD 2.18  0.05  2.24%   
LianBio ADR competes with Sensei Biotherapeutics, NextCure, Nuvation Bio, Inozyme Pharma, and Day One; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing LianBio ADR competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of LianBio ADR to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of LianBio ADR competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.182.182.18
Details
Intrinsic
Valuation
LowRealHigh
1.981.982.40
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as LianBio ADR. Your research has to be compared to or analyzed against LianBio ADR's peers to derive any actionable benefits. When done correctly, LianBio ADR's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in LianBio ADR.

LianBio ADR Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between LianBio ADR and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of LianBio and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of LianBio ADR does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
HOOK
+ 0.95
INZY
HOOK
+ 0.84
TERN
TERN
+ 0.82
INZY
HOOK
+ 0.8
NXTC
INZY
+ 0.77
NXTC
MACK
+ 0.72
NXTC
  
High negative correlations   
ELDN
- 0.78
INZY
ELDN
- 0.7
TERN
HOOK
- 0.68
ELDN
MACK
- 0.67
NUVB
ELDN
- 0.6
GRPH
ELDN
- 0.56
NXTC

Risk-Adjusted Indicators

There is a big difference between LianBio Stock performing well and LianBio ADR Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze LianBio ADR's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SNSE  6.95  0.47  0.04 (1.76) 7.60 
(8.65)
 10.20 
(13.21)
 110.76 
NXTC  2.65 (0.32) 0.00 (43.27) 0.00 
 0.00 
 5.22 
(5.52)
 21.68 
NUVB  3.40 (0.48) 0.00 (0.04) 0.00 
 0.00 
 9.48 
(8.36)
 21.30 
GRPH  2.36 (0.08) 0.00  0.48  0.00 
 0.00 
 4.79 
(4.73)
 14.40 
MACK  0.78 (0.05) 0.00  1.26  0.00 
 0.00 
 1.89 
(1.74)
 7.02 
INZY  2.99 (0.97) 0.00 (0.77) 0.00 
 0.00 
 5.84 
(7.92)
 16.32 
DAWN  1.99 (0.18) 0.00 (0.08) 0.00 
 0.00 
 3.71 
(3.69)
 11.05 
TERN  2.91 (0.57) 0.00 (0.39) 0.00 
 0.00 
 5.68 
(5.96)
 20.36 
ELDN  3.87  0.93  0.22  3.12  3.36 
(5.33)
 10.09 
(6.22)
 28.12 
HOOK  2.72 (1.32) 0.00 (1.80) 0.00 
 0.00 
 6.51 
(6.67)
 22.36 
All Fundamental Data

LianBio ADR Competitive Analysis

The better you understand LianBio ADR competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, LianBio ADR's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across LianBio ADR's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LIAN SNSE NXTC NUVB GRPH MACK INZY DAWN TERN ELDN
 2.24 
 2.18 
LianBio
 2.33 
 0.44 
Sensei
 0.92 
 1.08 
NextCure
 0.76 
 2.61 
Nuvation
 1.84 
 2.67 
Graphite
 1.01 
 11.96 
Merrimack
 1.68 
 3.03 
Inozyme
 0.47 
 12.75 
Day
 2.12 
 6.73 
Terns
 0.45 
 4.38 
Eledon
Market Volatility
(90 Days Market Risk)
Very steady
Abnormally volatile
Very risky
Risky
Very steady
Very steady
Slightly risky
Not too volatile
Somewhat reliable
Moderately volatile
Market Performance
(90 Days Performance)
Very Weak
Insignificant
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Above Average
Average
Dangerous
Dangerous
About Average
Average
Average
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Strong Buy
Not Available
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Cautious Hold
Not Rated
Not Rated
Cautious Hold
Hold
Cautious Hold
Cautious Hold
Current Ratio
15.81
23.46
33.87
33.58
27.07
31.85
14.54
31.45
23.59
22.22
Net Asset
319.96 M
74.37 M
128.04 M
621.48 M
188.46 M
19.19 M
200.85 M
376.05 M
268.52 M
125.89 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.83
N/A
N/A
EBITDA
(105.26 M)
(33.39 M)
(59.04 M)
(99.6 M)
(70.7 M)
(2.18 M)
(74.81 M)
(206.06 M)
(102.56 M)
(42.63 M)
Current Valuation
(182.65 M)
(31.59 M)
(39.67 M)
364.06 M
1.88 M
(20.36 M)
106.62 M
771.37 M
197.62 M
200.7 M
Price To Book
0.15
0.24
0.4
1.76
1.01
11.38
2.3
2.33
1.54
3.46
Operating Margin
N/A
N/A
N/A
-66.16
N/A
N/A
N/A
0.32
N/A
N/A
Retained Earnings
(470.52 M)
(231.9 M)
(324.48 M)
(342.8 M)
(367.05 M)
(548.82 M)
(285.93 M)
(458.58 M)
(332.63 M)
(243.19 M)
Current Asset
N/A
N/A
46.99 M
N/A
8 K
89.62 M
N/A
N/A
N/A
N/A
Beta
0.23
0.059
0.79
1.36
0.2
1.42
1.54
-1.52
-0.33
0.77
Number Of Employees
163
28
82
203
6
9
59
174
66
20
Shares Outstanding
108.06 M
25.15 M
28.01 M
335.57 M
58.24 M
14.79 M
64.24 M
100.85 M
84.94 M
59.74 M
Cash Flow From Operations
(83.53 M)
(32.02 M)
(52.97 M)
(68 M)
(90.01 M)
(1.52 M)
(70.67 M)
(146.85 M)
(67.39 M)
(39.53 M)
Annual Yield
0.96
N/A
N/A
N/A
0.3
N/A
N/A
N/A
N/A
N/A
Total Debt
4.34 M
6.21 M
6.61 M
4.01 M
362 K
N/A
46.59 M
408 K
603 K
383 K
Return On Equity
-0.32
-0.45
-0.55
-0.96
-0.52
-0.0112
-0.79
-0.18
-0.28
-0.25
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.22
-0.27
-0.31
-0.14
-0.18
-0.0107
-0.36
-0.25
-0.19
-0.33
Number Of Shares Shorted
378.13 K
226.71 K
50.44 K
14.07 M
704.04 K
842.49 K
3.41 M
19.49 M
5.39 M
686.69 K
Book Value Per Share
1.89
2.59
4.1
1.5
3.17
15.25
1.29
5.51
4.29
1.85
Current Liabilities
N/A
N/A
5.53 M
N/A
451 K
88.28 M
N/A
N/A
N/A
N/A
Total Asset
319.96 M
74.37 M
128.04 M
621.48 M
188.46 M
19.19 M
200.85 M
376.05 M
268.52 M
125.89 M
Debt To Equity
0.016
0.068
0.01
0.006
0.024
33.9
0.02
0.002
0.01
0.003
Short Ratio
0.4
0.29
1.89
5.52
7.93
8.65
7.59
15.63
3.93
0.75
Target Price
3.9
4.13
3.33
6.5
7.0
4.0
19.56
37.0
19.06
12.5
Shares Owned By Institutions
78.99
8.81
57.5
56.12
84.4
62.97
98.46
93.22
97.7
42.88
Market Capitalization
34.47 M
10.94 M
31.65 M
902 M
189.84 M
223.75 M
191.44 M
1.33 B
569.09 M
278.38 M
Price To Earnings To Growth
-0.04
N/A
0.03
N/A
-0.08
0.07
-0.06
N/A
N/A
0.01
Price To Earning
N/A
N/A
-25.44
N/A
0.7
65.7
N/A
3.88
N/A
N/A
Price To Sales
N/A
N/A
9.52
417.21
N/A
N/A
N/A
13.02
302.64
N/A
Net Income
(87.98 M)
(34.1 M)
(62.72 M)
(75.8 M)
(124.65 M)
(1.18 M)
(71.17 M)
(188.92 M)
(90.21 M)
(40.33 M)
Earnings Per Share
-0.82
-1.19
-2.08
-2.18
-2.19
-0.09
-1.56
-0.97
-1.18
0.73
Shares Owned By Insiders
5.9
34.39
8.85
26.85
9.17
1.19
0.5
17.01
0.15
0.04
Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Working Capital
289.16 M
61.61 M
105.84 M
602.46 M
183.22 M
18.74 M
181.56 M
345.77 M
255.49 M
52.23 M
Cash And Equivalents
329.3 M
123.71 M
185.49 M
703.8 M
322.29 M
13.36 M
151.48 M
394.86 M
139.81 M
70.46 M
Cash Per Share
3.04
4.03
6.68
3.22
5.54
1.0
3.77
5.38
5.51
5.12
Gross Profit
N/A
N/A
(54.2 M)
N/A
N/A
(9.1 M)
N/A
N/A
1000 K
N/A
Day Typical Price
2.17
0.44
1.09
2.6
2.69
11.94
2.98
12.68
6.72
4.43
Accumulation Distribution
0.0538
18942.28
2852.32
33101.25
0.0364
0.0142
75733.03
31088.11
107175.0
23523.93
Market Facilitation Index
0.12
N/A
0.0
N/A
0.1
0.17
N/A
0.0
N/A
0.0
Daily Balance Of Power
(0.42)
0.2
(0.12)
(0.22)
(0.50)
0.7059
0.1724
(0.13)
0.4
(0.08)
Period Momentum Indicator
(0.05)
0.01
(0.01)
(0.02)
(0.05)
0.12
0.05
(0.06)
0.14
(0.02)
Rate Of Daily Change
0.98
1.02
0.99
0.99
0.98
1.01
1.02
1.0
1.02
1.0
Day Median Price
2.17
0.44
1.09
2.6
2.7
11.93
2.96
12.65
6.72
4.45
Price Action Indicator
(0.01)
0.01
(0.01)
0.005
(0.06)
0.095
0.1
0.075
0.085
(0.08)
Coefficient Of Variation
2571.91
2875.75
(1,192)
(3,283)
(3,327)
(2,297)
(452.20)
(3,135)
(830.60)
526.8
Mean Deviation
2.99
6.95
2.65
3.4
2.36
0.7806
2.99
1.99
2.91
3.87
Jensen Alpha
0.0648
0.4741
(0.32)
(0.48)
(0.08)
(0.05)
(0.97)
(0.18)
(0.57)
0.9274
Total Risk Alpha
(0.36)
(1.20)
(0.77)
(0.72)
(0.48)
(0.20)
(1.35)
(0.39)
(0.93)
0.3232
Sortino Ratio
0.0157
0.0433
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.2234
Downside Variance
13.65
69.59
N/A
N/A
N/A
N/A
N/A
N/A
N/A
15.0
Standard Deviation
4.07
13.26
3.65
4.56
3.01
1.12
3.88
2.41
3.76
5.08
Kurtosis
1.8
32.69
2.44
0.8028
(0.19)
4.38
0.1746
(0.20)
0.6728
1.1
Potential Upside
6.76
10.2
5.22
9.48
4.79
1.89
5.84
3.71
5.68
10.09
Treynor Ratio
0.1602
(1.76)
(43.27)
(0.04)
0.4765
1.26
(0.77)
(0.08)
(0.39)
3.12
Maximum Drawdown
20.98
110.76
21.68
21.3
14.4
7.02
16.32
11.05
20.36
28.12
Variance
16.55
175.78
13.3
20.79
9.08
1.24
15.02
5.79
14.15
25.84
Market Risk Adjusted Performance
0.1702
(1.75)
(43.26)
(0.03)
0.4865
1.27
(0.76)
(0.07)
(0.38)
3.13
Risk Adjusted Performance
0.0364
0.0347
(0.05)
(0.01)
(0.01)
(0.03)
(0.15)
(0.02)
(0.08)
0.1462
Skewness
0.9
4.77
0.6599
0.3297
(0.14)
(0.85)
0.1295
(0.40)
0.3379
0.6402
Semi Deviation
3.34
7.6
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.36
Information Ratio
0.0143
0.0272
(0.11)
(0.05)
(0.06)
(0.13)
(0.25)
(0.07)
(0.15)
0.1701
Value At Risk
(5.00)
(13.21)
(5.52)
(8.36)
(4.73)
(1.74)
(7.92)
(3.69)
(5.96)
(6.22)
Expected Short fall
(3.44)
(8.65)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(5.33)
Downside Deviation
3.69
8.34
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.87
Semi Variance
11.15
57.83
N/A
N/A
N/A
N/A
N/A
N/A
N/A
11.26

LianBio ADR Competition Performance Charts

Five steps to successful analysis of LianBio ADR Competition

LianBio ADR's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by LianBio ADR in relation to its competition. LianBio ADR's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of LianBio ADR in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact LianBio ADR's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to LianBio ADR, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your LianBio ADR position

In addition to having LianBio ADR in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Asset Allocation ETFs Thematic Idea Now

Asset Allocation ETFs
Asset Allocation ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 145 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in LianBio Stock

If you are still planning to invest in LianBio ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LianBio ADR's history and understand the potential risks before investing.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY